Breaking Finance News

Zacks Investment Research downgraded Cantel Medical Corp. (NYSE:CMD) to Sell in a report released today.

Zacks Investment Research has downgraded Cantel Medical Corp. (NYSE:CMD) to Sell in a report released on 06/05/2017.

Just yesterday Cantel Medical Corp. (NYSE:CMD) traded 0.55% higher at $79.22. Cantel Medical Corp.’s 50-day moving average is $87.86 and its 200-day moving average is $78.49. The last stock price is up 21.91% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 74,464 shares of CMD traded hands, down from an average trading volume of 153,964

Recent Performance Chart

Cantel Medical Corp. (NYSE:CMD)

Cantel Medical Corp. has 52 week low of $68.19 and a 52 week high of $99.83 with a PE ratio of 55.96 and has a market capitalization of $0.

Brief Synopsis On Cantel Medical Corp. (NYSE:CMD)

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company's operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company's Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company's Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.